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ABSTRACT 
Objective: The management of early breast cancer (EBC) is performed with a series of treatments consisting of surgery and systemic therapy, along 
with long-term endocrine therapy for hormone responsive. The treatment generates a high illness effect that will affect the life quality of EBC 
patients. The objective of this study was to measure EBC patients’ quality of life after undergoing the treatment.  
Methods: A cross-sectional study was conducted by interviewing EBC patients using EQ-5D-5L instrument at private hospitals in Yogyakarta and 
Semarang, Indonesia. The EBC patients were women aged 18-60 y who had undergone surgery in 2010-2013 and received endocrine therapy.  
Results: Of the 71 patients identified, 45 patients were in disease-free survival (DFS) state, 8 patients were in locoregional recurrence (LR), and 18 
patients were in metastasis (M) state. Mobility and self-care problems occurred in patients who had metastasis (4.23%). The problem of usual activities 
occured in patients who had recurrence (22.54%). Most of the patients (84.51%) had pain problem, and all patients had an anxiety problem. The mean 
utility score (SD) in DFS patients was 0.841 (0.052), in LR patients was 0.758 (0.092), and in patients who had metastasis was 0.653 (0.104). The mean 
scores of EQ-5D VAS (SD) for EBC patients in DFS, LR and M health state were 86.56 (6.29), 81.88 (5.30), and 69.17 (5.75), respectively.  
Conclusion: The health states of EBC significantly affect HRQOL of patients. Efforts should be made to improve the quality of life of EBC patients 
especially in terms of pain and anxiety reduction. 
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Cancer is the second leading cause of death in the world. The incidence of 
cancer in 2030 is estimated to affect 26 million people and 17 million of 
them presumably die [1]. Breast cancer is a type of cancer mostly 
suffered and feared by women [2]. EBC is a surgical breast cancer since 
the cancer cells have not metastasized yet. EBC can occur in patients who 
have not been in menopause state (premenopausal) and who have been 
in menopause state (postmenopausal). Hormone-responsive testing is 
required to determine the type of therapy because adjuvant therapy is 
determined by hormone involvement (Estrogen Receptor) [3]. Based on 
Hospital Information System data throughout Indonesia in 2010, cases of 
hospitalization of breast cancer were 12.014 [1]. 
Breast cancer management is performed with a series of treatments 
including surgery, chemotherapy, radiation, endocrine therapy, and 
targetted therapy. This series of treatments is intended to destroy 
cancer cells or limit the progression of cancer and eliminate the 
symptoms [4]. A long duration of breast cancer treatment can have a 
high pain effect, bringing in even weaker conditions and depression. 
Such circumstances will affect the quality of life in patients with 
breast cancer [5, 6].  
Iinstruments that can be used to measure health-related quality of life 
(HRQOL) in cancer patients are a specific instrument and generic 
instrument [7]. Generic preferential-based measurements from HRQOL 
are commonly used in the economic evaluation of health interventions 
[8]. EQ-5D is a generic instrument widely used to evaluate HRQOL [9]. 
EQ-5D consists of two parts: the EQ-5D descriptive system and the EQ-
5D visual analogue (EQ-5D VAS). EQ-5D-5L is the latest version of EQ5D 
questionnaire. EQ-5D descriptive system can be reported as either a 
health profile or a weighted index. The weighted index is obtained by 
converting every health state of EQ-5D into a single summary index 
format called the EQ-5D index or utility. EQ-5D VAS records self-health 
values on a vertical and visual analogue. The scale ranges from 0, as the 
worst health state, up to 100, as the best health state. This information 
can be used as a quantitative measure of health outcomes assessed by 
individual respondents [10, 11]. 
Utility score is valuable in economic evaluation study and is required 
to calculate quality-adjusted life year (QALY), and subsequently to 
result in the cost-utility analysis (CUA) [12]. Utility generally ranges 
from 0 (death) to 1 (perfect health). This study aimed to measure 
the quality of life of EBC patients after undergoing the treatment. 
MATERIALS AND METHODS 
Subjects 
This study was a cross-sectional study, conducted by interviewing 
EBC patients using EQ-5D-5L questionnaire at private hospitals in 
Yogyakarta and Semarang, Indonesia in the period of January to June 
2017. Seventy-one EBC female patients with hormone-responsive, 
who have undergone surgery in 2010-2013 and received systemic 
therapy such as chemotherapy and endocrine therapy, were asked 
to participate in this study. 
Data collection and analysis 
Informed consents were provided to the 
patients before the interview. 
The patients were interviewed, and their medical records were 
reviewed to gain information regarding their clinical characteristics. 
The patients’ characteristics were gathered in terms of age, medical 
intervention and their health state.  
HRQOL was measured using the EQ-5D-5L instrument in the 
Indonesian language version. The EQ-5D-5L in official Indonesia 
language is provided by the Europol Group [13]. Utility (EQ-5D index 
score) values were calculated using the Indonesian value set [14]. 
Descriptive analysis was used to present the HRQOL in terms of 
patients’ health state, VAS and utility scores. 
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RESULTS AND DISCUSSION 
The mean age of the patients was 45.7 y old (SD=6.03). All patients 
had been through medical intervention as well as surgery, 
chemotherapy and endocrine therapy.  
 
Most patients did not receive radiation therapy (77.46%). Regarding 
the health states, the proportions of patients in the state of disease-
free survival (DFS), locoregional recurrence (LR) and metastasis (M) 
were 63.38%, 11.27%, and 25.35%, respectively (table 1). 
Table 1: Patient characteristics 
Characteristics n % 
Age (year) mean±SD 45.7±6.03 
Medical intervention Surgery  Yes 71  100 
  No 0  
 Chemotherapy Yes 71  100 
  No 0  
 Radiation therapy Yes 16  22.54 
  No 55  77.46 
 Endocrine therapy Yes 71  100 
  No 0  
Health states Disease-Free Survival 45  63.38 
 Locoregional Recurrence 8  11.27 
 Metastasis 18 25.35 
Descriptive statistics of EQ-5D regarding health state showed that m
 
obility and self-care problems occurred in the patients who had metastasis 
(4.23%). Problems of usual activities occured in the patients who had a recurrence (22.54%). Most of the patients (84.51%) had pain problem, and 
all of the patients had an anxiety problem (table 2).  
Table 2: Patients’ responses to EQ-5D-5L descriptive system 
Dimension Health states n (%) 
DFS LR M 
Mobility No problem 45 8 15 68 95.77 
Have problem 0 0 3 3 4.23 
Self-care No problem 45 8 15 68 95.77 
Have problem 0 0 3 3 4.23 
Usual activity No problem 45 4 6 55 77.46 
Have problem 0 4 12 16 22.54 
Pain/discomfort No problem 11 0 0 11 15.49 
Have problem 34 8 18 60 84.51 
Anxiety/depression No problem 0 0 0 0 0 
Have problem 45 8 18 71 100 
DFS=disease free survival, LR=locoregional recurrence, M=metastasis 
 
The EQ-5D health states of EBC patients showed that most of the 
patients had pain/discomfort problem and all of the patients had 
anxiety/depression. This study’s finding was similar to the results of 
previous studies in Penang, Malaysia [15] and Makasar, Indonesia [5]. 
The utility scores tended to decrease from health states DFS, LR 
to M. The mean utility score (SD) in the DFS patients was 0.841 
(0.052), in the LR patients was 0.758 (0.092), and in the patients 
who had metastasis was 0.653 (0.104). 
The mean scores of EQ-5D VAS (SD) were 86.56 (6.29), 81.88 
(5.30), and 69.17 (5.75) for EBC patients in health state DFS, LR 
and M, respectively (table 3). 
The VAS scores also 
tended to decrease from health states DFS, LR to M.  
  
Table 3: Descriptive of EQ-5D VAS score and EQ-5D index score classified by health states 
Health State EQ-5D VAS scores EQ-5D index scores 
Mean SD 95% CI of mean SE Mean SD 95% CI of mean SE 
Lower Upper Lower Upper 
DFS 86.56 6.29 84.67 88.45 0.94 0.841 0.052 0.825 0.856 0.008 
LR 81.88 5.30 77.44 86.31 1.88 0.758 0.092 0.681 0.835 0.032 
M 69.17 5.75 66.31 72.03 1.36 0.653 0.104 0.602 0.705 0.024 
 
*EQ-5D=Euro Quality of Life five dimension; VAS=visual analogue scale; 95%CI=95% confidence interval; SD=standard deviation; SE=standard error 
EBC significantly affects HRQOL of patients
The cancer itself, cancer treatment and non-cancer health condition 
were the contributors to cancer pain [16]. If not managed, cancer 
pain could link to emotional distress that leads to depression and 
anxiety [17, 18], which eventually worsen the patient’s quality of life. 
The history of having anxiety or trauma, avoiding coping style, social 
isolation, and life roles/caregiver; cancer-related fears; disease and 
treatment factors; as well as comorbidity such as pain, insomnia, 
fatigue, dyspnea, and depression were contributing factors of 
anxiety in cancer patients [19].  
. Therefore, efforts should 
be made to improve HRQOL of EBC patients especially in terms of 
pain/discomfort and anxiety/depression reduction. The 
recommendations to prevent and reduce anxiety in cancer patients 
are cognitive and behavioral interventions, relaxation training, 
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supportive counseling, and education; as well as pharmacologic 
interventions using medications such as anxiolytics and 
antidepressants [19]. This study also found that the EQ-5D VAS and 
utility scores tended to decrease from health states DFS, LR to M. 
CONCLUSION 
This study has confirmed that h
LIMITATION 
ealth states of EBC significantly 
affect HRQOL of patients. Efforts should be made to improve the 
quality of life of EBC patients especially in terms of pain/discomfort 
and anxiety/depression reduction. 
This study was conducted with a limited number of patients at two 
private hospitals in Java, and the findings may not be generalizable 
for another hospital or another country. However, the findings 
provide important information for future research since nearly all 
the health-related quality of life of EBC patients with hormone-
responsive lack evidence.  
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